首页> 美国卫生研究院文献>Cytotechnology >The enhancement of radiosensitivity in human esophageal squamous cell carcinoma cells by zoledronic acid and its potential mechanism
【2h】

The enhancement of radiosensitivity in human esophageal squamous cell carcinoma cells by zoledronic acid and its potential mechanism

机译:唑来膦酸增强人食管鳞状细胞癌细胞的放射敏感性及其潜在机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Esophageal squamous cell carcinoma (ESCC) has a low 5-year patient survival rate. Radiotherapy, as a preoperative or postoperative treatment of surgery, has a crucial role in improving local control and survival of ESCC. Various chemotherapeutic and biologic agents have been used as radio-sensitizers in combination with radiotherapy. Here, we demonstrate that zoledronic acid (ZOL) has a radio-sensitizing effect on ESCC cells. Exposure of ESCC cancer cells to ZOL plus radiation resulted in increased cell death through arresting the cell cycle between S and G2/M phases. ZOL appeared to inhibit proliferation, tube formation and invasion of endothelial cells. These anti-angiogenetic effects were more marked concurrently with irradiation. In addition, synergistic suppressive effects on VEGF expression were observed after combined treatment. Our data suggest that the combination of ZOL and radiation is a promising therapeutic strategy to enhance radiation therapy for ESCC patients.
机译:食道鳞状细胞癌(ESCC)的5年患者生存率较低。放射疗法作为手术的术前或术后治疗,在改善ESCC的局部控制和生存方面具有至关重要的作用。各种化学和生物制剂已与放射疗法结合用作放射增敏剂。在这里,我们证明唑来膦酸(ZOL)对ESCC细胞具有放射增敏作用。将ESCC癌细胞暴露于ZOL和放射线会导致细胞死亡的增加,这是因为其阻止了S和G2 / M期之间的细胞周期。 ZOL似乎抑制了内皮细胞的增殖,管形成和侵袭。这些抗血管生成作用在辐射的同时更明显。另外,联合治疗后观察到对VEGF表达的协同抑制作用。我们的数据表明,ZOL和放射线的结合是增强ESCC患者放射线治疗的有前途的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号